Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2020 | 1 |
2024 | 1 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
What is behind programmatic treatment outcome definitions for tuberculosis?
Eur Respir J. 2020 Jul 23;56(1):2001751. doi: 10.1183/13993003.01751-2020. Print 2020 Jul.
Eur Respir J. 2020.
PMID: 32703821
Free article.
No abstract available.
Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma.
de Bruyn DP, van Poppelen NM, Brands T, van den Boom SC, Eikenboom E, Wagner A, van Veghel-Plandsoen MM, Geeven G, Beverloo B, van Rij CM, Verdijk RM, Naus NC, Bagger MM, Kiilgaard JF, de Klein A, Brosens E, Kiliç E.
de Bruyn DP, et al.
Invest Ophthalmol Vis Sci. 2024 Feb 1;65(2):11. doi: 10.1167/iovs.65.2.11.
Invest Ophthalmol Vis Sci. 2024.
PMID: 38319670
Free PMC article.
Item in Clipboard
Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.
Migliori GB, Nardell E, Yedilbayev A, D'Ambrosio L, Centis R, Tadolini M, van den Boom M, Ehsani S, Sotgiu G, Dara M.
Migliori GB, et al.
Eur Respir J. 2019 Jun 5;53(6):1900391. doi: 10.1183/13993003.00391-2019. Print 2019 Jun.
Eur Respir J. 2019.
PMID: 31023852
Free article.
Review.
Evidence-based guidance is needed on 1) how tuberculosis (TB) infectiousness evolves in response to effective treatment and 2) how the TB infection risk can be minimised to help countries to implement community-based, outpatient-based care.This document aims to 1) review the avai …
Evidence-based guidance is needed on 1) how tuberculosis (TB) infectiousness evolves in response to effective treatment and 2) how the TB in …
Item in Clipboard
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.
Borisov S, et al.
Eur Respir J. 2019 Dec 19;54(6):1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec.
Eur Respir J. 2019.
PMID: 31601711
Free article.
Item in Clipboard
Cite
Cite